Abbott study highlights long-term benefits of HeartMate 3 device

Abbott has announced the findings of a new study showing the long-term benefits offered by its HeartMate 3 left ventricular assist device (LVAD).

The company has reported positive data from the MOMENTUM 3 study, the world's largest LVAD trial evaluating patients in need of both short-term and long-term support in a single study.

HeartMate 3 was associated with superior rates of event-free survival compared to the older HeartMate II device, with the newer system also delivering improved survival rates, low pump thrombosis and a reduced occurrence of strokes.

In addition, patients receiving the HeartMate 3 LVAD experienced significant improvements compared to HeartMate II in terms of functional capacity and quality of life scores at two years compared to baseline.

Dr John O'Connell, medical director for mechanical circulatory support at Abbott, said: "Data from the MOMENTUM 3 study show Abbott's significant progress in LVAD innovation and how it's improving patient health outcomes."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.